Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
企業コードBVS
会社名Bioventus Inc
上場日Feb 11, 2021
最高経営責任者「CEO」Mr. Robert E. Claypoole
従業員数930
証券種類Ordinary Share
決算期末Feb 11
本社所在地4721 Emperor Boulevard, Suite 100
都市DURHAM
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号27703
電話番号19194746700
ウェブサイトhttps://www.bioventus.com/
企業コードBVS
上場日Feb 11, 2021
最高経営責任者「CEO」Mr. Robert E. Claypoole
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし